CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CG Oncology, Inc. Common stockNASDAQ: CGON

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $39.22M rose 40.7% year over year, behind the +47.7% change in trailing-twelve-month research & development. Sequentially, it fell 28.2% from the prior quarter. Over 3 fiscal years it compounded at +59.0% a year.

Context

  • Research & development amounted to 2887.2% of revenue in FY2025, down 4321.1 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +40.7% toward the trailing-twelve-month pace of +47.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$39.22M-28.2% QoQ
Last fiscal yearDec 2025
$116.64M+42.1% YoY
LTMSep 2026
$167.57M+47.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.7%——
1 year+42.1%——
3-year CAGR+59.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
116.64M USD
Year-over-year change
+42.1%
4-year CAGR
+58.9%

Research & Development vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 research & development of $167.57M is the 2nd highest of the 3 companies compared; the peer median is $157.53M.
  • Its year-over-year change of +47.7% is the highest of 3, against a peer median of +17.6%.
  • Research & development amounts to 2717.6% of revenue for CGON, versus a peer median of 91.4%.
CGON Competitors Peer median
Research & Development for CGON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M +33.2%-5.7%138.2%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$167.57M +47.7%+59.0%2717.6%
URGNUroGen Pharma Ltd.LTM Mar 2026$62.83M +2.1%+8.2%44.7%
Peer median (excluding CGON) $157.53M+17.6%+1.3%91.4%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.36M191K204K1.14M4.04M
Cost of Revenue10K15K45.75M82.1M4.65M
Gross Profit10.35M176K(45.55M)(80.96M)(607K)
Gross Margin99.9%92.1%-22327.5%-7108.3%-15.0%
Research & Development18.32M29.03M45.75M82.1M116.64M
Selling, General & Admin4.64M6.39M9.9M33.7M73.53M
Operating Expenses22.95M35.42M9.9M33.7M190.17M
Depreciation & Amortization10K15K17K32K1.45M
EBITDA(12.38M)(35.43M)(48.59M)(88.01M)(159.55M)
EBITDA Margin-119.5%-18548.2%-23818.6%-7726.7%-3949.3%
Operating Income(12.61M)(35.25M)(55.45M)(114.67M)(190.77M)
Operating Margin-121.7%-18453.4%-27180.9%-10067.3%-4722.1%
Interest Income006.9M26.62M29.93M
Interest Expense451K1K000
Other Income / Expenses(233K)(197K)6.84M26.63M29.78M
Income Before Tax(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Pre-Tax Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
Income Tax Expense00000
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Net Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
EPS (Basic)(0.28)(0.66)(1.02)(1.41)(2.08)
EPS (Diluted)(0.28)(0.66)(1.02)(1.41)(2.08)
Weighted Avg Shares66.64M66.64M66.64M62.5M77.3M
Weighted Avg Shares (Diluted)66.64M66.64M66.64M62.5M77.3M

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.